CellBri

About CellBri

Shenzhen Cellbri Bio-Innovation Technology, founded in 2020 and headquartered in Shenzhen, China, develops and manufactures solutions for the cell and gene therapy (CGT) industry. The company provides automated cell processing systems designed to assist therapy developers and Contract Development and Manufacturing Organizations (CDMOs) in reducing costs and streamlining production timelines.

Cellbri's business model centers on providing modular and all-in-one automated systems for various stages of cell therapy manufacturing, including cell processing, separation, and transfection. Their product lineup is engineered for scalability, enabling clients to transition from early-stage research and development to commercial-scale production. The company's offerings include the 'Gentle Series' of modular systems and the 'CellFAB Series' for all-in-one processing, which are designed to be flexible and not lock clients into proprietary reagents. Their products, such as the Gentle Flex Pro, are fully enclosed, automated systems capable of handling tasks like PBMC separation, viral transduction, cell washing, and harvest. These systems are 21 CFR Part 11 compliant, ensuring digital traceability for GMP alignment.

The company serves a client base that includes pharmaceutical companies, academic institutions, biotechnology firms, and research centers. By providing closed, digital, and configurable systems, Cellbri aims to reduce manual steps, improve batch success rates, and enhance consistency in cell therapy development. The firm has raised a total of $28M in funding through multiple venture capital rounds, with investors including Changzhou Hi-tech Group, Fosun Health Capital, and 3E Bioventures.